Dalazatide

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (3S)-3-[[4-[[2-[[3-(dimethylamino)propyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoic acid | image = | width = | alt = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 123456-78-9 | ATC_prefix = | ATC_suffix = | PubChem = 123456 | DrugBank = DB12345 | ChemSpiderID = 123456 | UNII = | KEGG = | ChEBI = | ChEMBL = | synonyms = }}

Dalazatide is a peptide-based drug that acts as a selective inhibitor of the Kv1.3 potassium channel. It is being investigated for its potential use in treating autoimmune diseases such as multiple sclerosis, psoriasis, and rheumatoid arthritis. The drug is derived from a naturally occurring peptide found in the venom of the sea anemone Anemonia sulcata.

Mechanism of Action

Dalazatide works by selectively blocking the Kv1.3 potassium channel, which is predominantly expressed in effector memory T cells. These T cells are implicated in the pathogenesis of several autoimmune diseases. By inhibiting Kv1.3, dalazatide reduces the activity of these T cells, thereby modulating the immune response and potentially alleviating symptoms of autoimmune conditions.

Clinical Development

Dalazatide has undergone several phases of clinical trials to evaluate its safety and efficacy. Early studies have shown promise in reducing the severity of symptoms in patients with autoimmune diseases. However, further research is needed to fully establish its therapeutic potential and to determine the optimal dosing regimen.

Potential Applications

The primary focus of dalazatide's development is in the treatment of autoimmune diseases. Its ability to selectively target Kv1.3 channels makes it a promising candidate for conditions where effector memory T cells play a critical role. This includes diseases such as:

• Multiple Sclerosis
• Psoriasis
• Rheumatoid Arthritis

Side Effects and Safety

As with any investigational drug, dalazatide's safety profile is still being established. Common side effects observed in clinical trials include mild to moderate injection site reactions, headache, and fatigue. Long-term safety data is still being collected.

Research and Future Directions

Ongoing research is focused on further elucidating the role of Kv1.3 channels in autoimmune diseases and exploring dalazatide's potential in other therapeutic areas. Researchers are also investigating combination therapies that may enhance the efficacy of dalazatide.

Also see

• Kv1.3 Potassium Channel
• Autoimmune Disease
• Peptide Therapeutics